Abstracts tagged "Adverse events"

Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Roberto Ranza¹, David C Titton², Valeria Vallim³, Ines Silveira⁴, Aline Ranzolin⁵, Andre Hayata⁶, Mirhelen M. Abreu⁷, Paulo Louzada-Jr⁸, Angela LBP Duarte⁵, Claiton Brenol⁹, Geraldo C Pinheiro¹⁰, Glaucio R Castro¹¹, Hellen M Carvalho¹², Isaias Costa¹³, Jose C Macieira¹⁴, Jose R Miranda¹⁵, Julio CM Bertacini¹⁶, Luis SG Barbosa¹⁷, Manoel B Bertolo¹⁸, Marcelo M. Pinheiro¹², Maria F Sauma¹⁹, Marilia B Silva²⁰, Marlene Freire²¹, Roberto A Toledo²² and Vander Fernandes²³, ¹Universidade Federal de Uberlandia, Uberlandia MG, Brazil, ²Hospital de Clínicas da UFPR, Curitiba PR, Brazil, ³Universidade Federal do Espirito Santo, Vitoria ES, Brazil, ⁴PUCRS, Porto Alegre RS, Brazil, ⁵Universidade Federal de Pernambuco, Recife PE, Brazil, ⁶CRO Osasco, Osasco SP, Brazil, ⁷Universidade Federal de São Carlos, São Carlos SP, Brazil, ⁸USP RP, Ribeirão Preto SP, Brazil, ⁹Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ¹⁰UERJ, Rio de Janeiro RJ, Brazil, ¹¹Hospital Governador Celso Ramos, Florianopolis SC, Brazil, ¹²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ¹³Universidade Federal MS, Campo Grande MS, Brazil, ¹⁴UFS Aracaju, Aracaju SE, Brazil, ¹⁵Artrocenter Clinica Medica, Taubate SP, Brazil, ¹⁶USP SP CDMAC, São Paulo SP, Brazil, ¹⁷Universidade Federal Mato Grosso, Cuiabá MT, Brazil, ¹⁸UNICAMP, Campinas SP, Brazil, ¹⁹UFPA, Belem PA, Brazil, ²⁰Hospital Universitario Evangelico, Curitiba PR, Brazil, ²¹UFTM, Uberaba MG, Brazil, ²²FUNFARP, São José do Rio Preto SP, Brazil, ²³Universidade de Cuiabá, Cuiaba MT, Brazil
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…
Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases
Takayuki Katsuyama¹, Sayaka Aoki², Ken-ei Sada³, Yuriko Yamamura¹, Haruki Watanabe¹, Eri Katsuyama¹, Mariko Narazaki¹, Noriko Tatebe¹, Koichi Sugiyama¹, Katsue S. Watanabe³, Hiroshi Wakabayashi¹, Tomoko Kawabata¹, Jun Wada⁴ and Hirofumi Makino³, ¹Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…
Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Daniel J. Wallace¹, Josep Ordi-Ros², C. Michael Neuwelt³, Kenneth Kalunian⁴, Michelle A. Petri⁵, Slawomir Jeka⁶, Ronald F. van Vollenhoven⁷, Brian Kilgallen⁸, Sabine Bongardt⁹, Caroline Gordon¹⁰ and Vibeke Strand¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Vall De Hebron General Hospt, Barcelona, Spain, ³East Bay Rheumatology Research Institute, San Leandro, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶2nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, ⁷Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ¹¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting
Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry
Lene Dreyer¹, Lene Mellemkjær², Inger Marie Jensen Hansen³ and Merete Lund Hetland⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Shunichi Kumagai¹, Yoshiaki Hagiwara², Yoshihide Ichise¹, Sho Sendo³, Nobuhiko Okada¹, Jun Saegusa⁴ and Goh Tsuji⁵, ¹Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ²Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Mike Nurmohamed¹, Yanjun Bao², James Signorovitch³, Parvez M. Mulani⁴ and Daniel Furst⁵, ¹VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, ²AbbVie, North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
Abstract Number: 1150 • 2012 ACR/ARHP Annual Meeting
Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project
Sarah Ringold¹, Audrey F. Hendrickson², Carol A. Wallace³ and Rachel E. Sobel⁴, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, Seattle Children's Research Institute, Seattle, WA, ³Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁴Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY
Background/Purpose: There are few data available regarding the rates of serious and important medical events (SAEs and IMEs) for most of the medications used to…
Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…
Abstract Number: 2640 • 2012 ACR/ARHP Annual Meeting
Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Gail S. Kerr⁴, Andreas M. Reimold⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the most commonly used medication for patients with rheumatoid arthritis (RA), however, the frequency of MTX adverse events (AE) has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].